When it comes to developing cancer treatments, the pharmaceutical industry has long prioritized drugs for conditions that disproportionately turn up in patients in the West. That might be changing.
Original Article: STAT Plus: Chinese patients get these cancers at an alarming rate. Now drug makers see an opportunity